TuHURA Biosciences Inc

HURA

Company Profile

  • Business description

    TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

  • Contact

    10500 University Center Drive
    Suite 110
    TampaFL33612
    USA

    T: +1 813 875-6600

    https://www.tuhurabio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    19

Stocks News & Analysis

stocks

Unconventional wisdom: Are dividends the answers?

As investors toil in complexity the obvious solution may be the right one.
stocks

Netflix: A business that’s nearly flawless

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks

Trump’s US dollar assault is fuelling CBA’s rise

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,934.1045.30-0.50%
CAC 407,818.2832.15-0.41%
DAX 4024,295.9355.110.23%
Dow JONES (US)44,693.91316.38-0.70%
FTSE 1009,138.3776.880.85%
HKSE25,667.18129.110.51%
NASDAQ21,057.9637.940.18%
Nikkei 22541,701.94124.40-0.30%
NZX 50 Index12,829.6624.530.19%
S&P 5006,363.354.440.07%
S&P/ASX 2008,664.2045.20-0.52%
SSE Composite Index3,604.681.05-0.03%

Market Movers